(Corrects consensus figure to million from billion)
Nov 3 (Reuters) – French biotechnology firm Biomérieux reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase in sales from GO 28 growth drivers.
Total sales for the period came in at €1,042 million ($1.17 billion), up 8% year on year, above the company’s compiled median consensus for sales of €1,007 million (not billion) and organic growth of 5.9%.
($1 = 0.8937 euros)
(Reporting by Margaux Perrin in Gdansk, editing by Izabela Niemiec)
Comments